Tacrolimus 0,03% administration in atopic dermatitis children
- Authors: Pampura AN1, Fedenko ES2
-
Affiliations:
- Moscow research Institute of Pediatric and child surgery
- Institute of Immunology
- Issue: Vol 10, No 4 (2013)
- Pages: 69-73
- Section: Articles
- Submitted: 10.03.2020
- Published: 15.12.2013
- URL: https://rusalljournal.ru/raj/article/view/546
- DOI: https://doi.org/10.36691/RJA546
- ID: 546
Cite item
Abstract
The article is devoted to natural course of atopic dermatitis in children and new trends in topical treatment with tacrolimus 0,03%.
Keywords
Full Text
About the authors
A N Pampura
Moscow research Institute of Pediatric and child surgery
Email: apampura@pedklin.ru
Moscow, Russia
E S Fedenko
Institute of ImmunologyMoscow, Russia
References
- Bieber T. Atopic Dermatitis. N. Engl. J. Med. 2008, v. 358, p. 1483-1494.
- Akdis C., Akdis M., Bieber T. et al. Diagnosis and treatment of atopic dermatitis in children and adults: European Academy of Allergology and Clinical Immunology/ American Academy of Allergy, Asthma and Immunology/PRACTALLConsensus Report. J. Allergy Clin. Immunol. 2006, v. 118, p. 152-169.
- Баранов A.A. и соавт. Атопический дерматит у детей: диагностика, лечение и профилактика. Научно-практическая программа. 2000, с. 53-62.
- Российский национальный согласительный документ по атопическому дерматиту. Под ред. РМ. Хаитова, А.А. Кубановой. Атопический дерматит: рекомендации для практических врачей. М., «Фармарус принт». 2002, с. 24.
- Dumont F.J. Mechanisms of action of cyclusporin A and tacrolimus (FK506). Principls of Drag Development in Transplantation and Autoimmuniny. R. Lieberman, A. Mukherjee (Eds). R.G. Landes Company. 1996, v. 1, p. 133-155.
- Fleischer A. Treatment of atopic dermatitis: Role of tacrolimus ointment as a topical noncorticosteroid therapy. J. Allergy Clin. Immunol. 2000, v. 104, p. 126-130.
- Panhans-Gross A., Novak N., Kraft S. et al. Human epidermal Langerhans’ cells are targets for the immnosuppressive macrolide tacrolimus (FK506). J. Allergy Clin. Immunol. 2001, v. 107, p. 345-352.
- Nakagawa H., Etoh T., Yokota Y. et al. Tacrolimus has antifungal activities against Malassezia furfur isolated from healthy adults and patients with atopic dermatitis. Clin. Drug Invest. 1996, v. 12, p. 244-250.
- Pournaras C.C., Lubbe J., Saurat J.H. Staphylococcal colonization in atopic dermatitis treatment with topical tacrolimus (Fk506). J. Invest. Dermatol. 2001, v. 116, p. 480-481.
- Reitamo S., Rissanen J., Remitz A. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J. Invest. Dermatol. 1998, v. 111, p. 396-398.
- Mandelin J.M., Rubins A., Remitz A. et al. Long-term efficacy and tolerability of tacrolimus 0.03% ointment in infants: a two-year open-label study. Int. J. Dermatol. 2012, v. 51, p. 104-110.
- Bieber T. Topical tacrolimus (FK506): a new milestone in the management of atopic dermatitis. J. Allergy Clin. Immunol. 1998, v. 102, p. 555-557.
- Allen A., Siegfried E., Silverman R. et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch. Dermatol. 2001, v. 137, p. 747-750.
- Chen S.L., Yan J., Wang F. S. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta analysis of randomized clinical trials. J. Dermatol. Treatment. 2010, v. 21, p. 144-156.
- Boguniewicz M., Fiedler V.C., Raimer S. et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children. J. Allergy Clin. Immunol. 1998, v. 102, p. 637-644.
- Reitamo S., Harper J., Bos J.D. et al. 0,03% Tacrolimus ointment applied once or twice daily is more efficacious than 1% hydrocortisone acetate in children with moderate to severe atopic dermatitis: Results of a randomized double-blind controlled trial. Br. J. Dermatol. 2004, v. 150, p. 554-562.
- Paller A.S., Lebwohl M., Fleischer A.B. et al. Tacrolimus ointment is more effective than pimecrolimus cream with a similar safety profile in the treatment of atopic dermatitis: Results from 3 randomized, comparative studies. J. Am. Acad. Dermatol. 2005, v. 52, p. 810-822.
- Reitamo S., Rustin M., Ruzicka T. et al. Efficacy and safety of tacrolimus ointment compared with hydrocortisone butyrate ointment in adult patients with atopic dermatitis. J. Allergy Clin. Immunol. 2002, v. 109, p. 547-555.
- Jaracz E., Fleischer A., Rico M.J. et al. Tacrolimus ointment for the treatment of atopic dermatitis: Focus on cutaneous infections. 2001. Washington DC. Conference Proceeding.
- Lubbe J., Pournaras C.C., Saurat J.H. Eczema herpeticum during treatment of atopic dermatitis with 0,1% tacrolimus ointment. Dermatology. 2000, v. 201, p. 249-251.
- Wollenberg A., Reitamo S., Atzori F. et al. Proactive treatment of atopic dermatitis in adults with 0,1% tacrolimus ointment. Allergy. V. 63, р. 742-750.
- Thaci D., Reitamo S., Ensenat MAG. et al. Proactive disease management with 0,03% tacrolimus ointment for children with atopic dermatitis: results of a randomized, multicentre, comparative study BJD. 2008, v. 159, p. 1348-1356.